Monday, June 15, 2:00 – 3:30 pm
Auditorium Lulli

Chairs: Frank Zerbib (France) – Nikki Johnston (USA)

1. What does the San Diego Consensus change in clinic? – Thomas L. Carroll (USA)
2. Is GMA biomarker subtyping the key to understanding and treating GERD/LPR? – Mark Noar (USA)
3. Alginate, H2RA, PPI, neuromodulation, or lifestyle first—what’s your first script? – Jacqui Allen (New Zealand)
4. What is the current understanding of the role of reflux in promoting laryngopharngeal cancer? – Jérôme R. Lechien (Belgium)
5. Are PCABs effective for LPRD? – Carmelo Scarpignato (Italy) 
6. What is the status of pepsin inhibitors for LPR? – Nikki Johnston (USA)
7. Which surgical or endoscopic options work for extra-esophageal disease? Stefano Siboni (Italy)
8. Pediatrics: are kids just little adults when it comes to LPRD? – (TBA)

Motion: “This house supports the San Diego Consensus Statement as the governing guideline for LPRD.”

• FOR: Walter W. Chan (USA) – (defending the Consensus statements & pathways).
• AGAINST: Inna Husain (USA) – (challenging external validity, symptom-first pathways, and laryngology-specific nuances).

Case-Based Panel + Audience Interaction:

1. Professional singer with chronic throat clearing and normal EGD: “Treat or test first?”
   Panel: Martin Birchall (UK) – Inna Husain (USA) – Mark Noar (USA)
2. Chronic cough with normal acid exposure but high non-acid events: “Does therapy change?”
   Panel: Thomas L. Carroll (USA) – ​Jonathan Bock (USA) – Jacqui Allen (New Zealand)
3. Mucosal protection: formulations and their place in the management of GERD and LPR
   Panel: Carmelo Scarpignato (Italy) – Edoardo Savarino (Italy) – Serhat Bor (Turkey)
4. Refractory LPS after maximal PPI & alginate: “Is it time for surgery or is it not reflux?”
   Panel: Stefano Siboni (Italy) – Jonathan Gould (USA) – Jérôme R. Lechien (Belgium)

3 take-home messages aligned to consensus language: Frank Zerbib (France)